Organogenesis Holdings (ORGO) Research & Development (2017 - 2026)

Organogenesis Holdings' Research & Development history runs 10 years deep, the most recent figure standing at $15.2 million for Q1 2026.

• In Q1 2026, Research & Development rose 42.49% year-over-year to $15.2 million; the TTM figure through Mar 2026 stood at $49.1 million (up 2.0% YoY), while the FY2025 annual figure was $44.5 million, down 11.4% from the prior year.
• Research & Development was $15.2 million for Q1 2026 at Organogenesis Holdings, up from $10.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $15.6 million in Q2 2024 to a low of $8.6 million in Q1 2022.
• Historically, Research & Development has averaged $11.4 million across 5 years, with a median of $10.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 42.5% in 2024, then sank 33.31% in 2025.
• A 5-year view of Research & Development shows it stood at $11.4 million in 2022, then rose by 3.29% to $11.8 million in 2023, then slipped by 2.04% to $11.5 million in 2024, then slipped by 10.79% to $10.3 million in 2025, then surged by 47.39% to $15.2 million in 2026.
• The last three Research & Development figures came in at $15.2 million (Q1 2026), $10.3 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.